BioLineRx Announces FDA Approval of APHEXDA(TM) (motixafortide) in Combination with Filgrastim (G-CSF) to Mobilize Hematopoietic Stem Cells for Collection and Subsequent Autologous Transplantation in Patients with Multiple Myeloma

Stock Information for BioLineRx Ltd.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About BioLineRx Ltd.

BioLineRx Announces New Pilot Phase Data from Phase 2 Combination Trial of Motixafortide in First-Line Pancreatic Cancer (PDAC) to be Presented at ASCO 2025 Annual Meeting
BioLineRx Reports First Quarter 2025 Financial Results and Provides Corporate Update
BioLineRx to Report First Quarter 2025 Results on May 27, 2025
BioLineRx Reports 2024 Financial Results and Provides Corporate Update
BioLineRx to Report 2024 Annual Results on March 31, 2025
BioLineRx Issues Letter to Shareholders
BioLineRx Announces Change to Ratio of American Depositary Shares to Ordinary Shares
BioLineRx Announces $10 Million Registered Direct Offering

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.